Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Niraparib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03840967
What this trial is testing

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Who this might be right for
Esophageal CancerGastric CancerAdenocarcinoma
Shadia Jalal, MD 14
Large-scale testing (Phase 3)Looking for participantsNCT05009082
What this trial is testing

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AGO Study Group 970
Early research (Phase 1)Study completedNCT03154281
What this trial is testing

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Who this might be right for
Breast CancerOvarian Cancer
Avera McKennan Hospital & University Health Center 14
Early research (Phase 1)Ended earlyNCT01110603
What this trial is testing

MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Who this might be right for
Cancer: Solid Tumors
Tesaro, Inc. 12
Early research (Phase 1)Ended earlyNCT03209401
What this trial is testing

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Who this might be right for
Solid Tumor, AdultHomologous Recombination Deficiency
Georgetown University 23
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Testing effectiveness (Phase 2)Study completedNCT03601923
What this trial is testing

Niraparib in Patients With Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Dana-Farber Cancer Institute 32
Very early researchActive Not RecruitingNCT05406700
What this trial is testing

Niraparib In Recurrent IDH 1/2 Gliomas

Who this might be right for
Low-grade GliomaIDH2 Gene MutationRecurrent Glioma+2 more
Massachusetts General Hospital 16
Early research (Phase 1)Study completedNCT04481113
What this trial is testing

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+17 more
OHSU Knight Cancer Institute 8
Testing effectiveness (Phase 2)UnknownNCT03925350
What this trial is testing

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Who this might be right for
Metastatic Melanoma
California Pacific Medical Center Research Institute 41
Testing effectiveness (Phase 2)Study completedNCT03308942
What this trial is testing

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Who this might be right for
Neoplasms
Tesaro, Inc. 53
Early research (Phase 1)Active Not RecruitingNCT04502602
What this trial is testing

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Who this might be right for
Advanced Solid TumorOvarian Cancer
Virginia Commonwealth University 18
Not applicableUnknownNCT04617470
What this trial is testing

Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study

Who this might be right for
Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04992013
What this trial is testing

Niraparib in Tumors Metastatic to the CNS

Who this might be right for
Metastatic CancerCentral Nervous System Cancer
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)UnknownNCT03553004
What this trial is testing

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial

Who this might be right for
Pancreatic Cancer
University of Kansas Medical Center 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04837209
What this trial is testing

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Massachusetts General Hospital 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255
What this trial is testing

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Who this might be right for
Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more
Dana-Farber Cancer Institute 62
Early research (Phase 1)Study completedNCT03695380
What this trial is testing

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Who this might be right for
OVARIAN CANCER
Hoffmann-La Roche 77
Testing effectiveness (Phase 2)UnknownNCT05162196
What this trial is testing

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Who this might be right for
Recurrent Small Cell Lung Cancer
Wuhan University 57
Testing effectiveness (Phase 2)Study completedNCT04508803
What this trial is testing

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Who this might be right for
Treatment Efficacy
Fudan University 37
Next Page